Inflammatory Myofibroblastic Tumor of the Mesentery with a SQSTM1::ALK Fusion Responding to Alectinib

Overview

Journal Cancer Rep (Hoboken)

Specialty Oncology

Date 2023 Feb 8

PMID 36754839

Authors

Cass G G Sunga

Michael S Higgins

Robert W Ricciotti

Yajuan J Liu

Lee D Cranmer

Affiliations

Soon will be listed here.

Abstract

Background: Inflammatory myofibroblastic tumor (IMT) is an ultra-rare soft tissue neoplasm associated with fusion proteins encompassing the anaplastic lymphoma kinase (ALK) protein fused to a variety of partner proteins. Data regarding response to ALK-targeting agents based on fusion partner is limited.

Case: A 30-year-old female sought emergency care after onset of abdominal and lower back pain in 2019. Computed tomography (CT) demonstrated a cystic, mesenteric mass within the pelvis measuring up to 8.9 cm. Complete laparoscopic excision of the mass from the mesentery of the right colon and terminal ileum was performed. Pathologic assessment revealed IMT with a fusion between sequestosome 1 and ALK (SQSTM1::ALK), described in only two other cases of IMT. Four months after surgery, CT revealed multi-focal, unresectable disease recurrence. She was referred to the University of Washington/Fred Hutchinson Cancer Center and placed on therapy with alectinib, after which she experienced a partial response. Three years after IMT recurrence, disease remains under control.

Conclusion: This is the third reported case of IMT associated with the novel SQSTM1::ALK fusion protein, and the second treated with alectinib. Treatment with the ALK inhibitor alectinib appears to be active in this setting.

Citing Articles

Partial Response to Treatment with ALK Inhibitor in a Patient With SQSTM1-ALK Fusion Positive Lung Adenocarcinoma.

Rodriguez Arroyo B, Mondragon-Cardona A, Pacheco-Orozco R, Tamayo A, Moreno J, Baena-Valencia J Eur J Case Rep Intern Med. 2024; 11(12):004887.

PMID: 39651381 PMC: 11623360. DOI: 10.12890/2024_004887.

Inflammatory myofibroblastic tumor from molecular diagnostics to current treatment.

Chmiel P, SlOWIKOWSKA A, Banaszek L, Szumera-Cieckiewicz A, Szostakowski B, Spalek M Oncol Res. 2024; 32(7):1141-1162.

PMID: 38948020 PMC: 11209743. DOI: 10.32604/or.2024.050350.

Update of Diagnosis and Targeted Therapy for ALK Inflammation Myofibroblastic Tumor.

Wang Q, Chen H, Wu R, Wu C Curr Treat Options Oncol. 2023; 24(12):1683-1702.

PMID: 37938503 PMC: 10781869. DOI: 10.1007/s11864-023-01144-6.

Inflammatory myofibroblastic tumor of the mesentery with a SQSTM1::ALK fusion responding to alectinib.

Sunga C, Higgins M, Ricciotti R, Liu Y, Cranmer L Cancer Rep (Hoboken). 2023; 6(3):e1792.

PMID: 36754839 PMC: 10026288. DOI: 10.1002/cnr2.1792.

References

Butrynski J, DAdamo D, Hornick J, Dal Cin P, Antonescu C, Jhanwar S . Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med. 2010; 363(18):1727-33. PMC: 3014292. DOI: 10.1056/NEJMoa1007056. View

Sirvent N, Hawkins A, Moeglin D, Coindre J, Kurzenne J, Michiels J . ALK probe rearrangement in a t(2;11;2)(p23;p15;q31) translocation found in a prenatal myofibroblastic fibrous lesion: toward a molecular definition of an inflammatory myofibroblastic tumor family?. Genes Chromosomes Cancer. 2001; 31(1):85-90. DOI: 10.1002/gcc.1121. View

Honda K, Kadowaki S, Kato K, Hanai N, Hasegawa Y, Yatabe Y . Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report. Invest New Drugs. 2019; 37(4):791-795. DOI: 10.1007/s10637-019-00742-2. View

Patel A, Murphy K, Hawkins A, Cohen J, Long P, Perlman E . RANBP2 and CLTC are involved in ALK rearrangements in inflammatory myofibroblastic tumors. Cancer Genet Cytogenet. 2007; 176(2):107-14. DOI: 10.1016/j.cancergencyto.2007.04.004. View

Kazakov D, Kyrpychova L, Martinek P, Grossmann P, Steiner P, Vanecek T . ALK Gene Fusions in Epithelioid Fibrous Histiocytoma: A Study of 14 Cases, With New Histopathological Findings. Am J Dermatopathol. 2018; 40(11):805-814. DOI: 10.1097/DAD.0000000000001085. View

Brenner A, Gunnes M . Therapeutic Targeting of the Anaplastic Lymphoma Kinase (ALK) in Neuroblastoma-A Comprehensive Update. Pharmaceutics. 2021; 13(9). PMC: 8470592. DOI: 10.3390/pharmaceutics13091427. View

Hida T, Nokihara H, Kondo M, Kim Y, Azuma K, Seto T . Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017; 390(10089):29-39. DOI: 10.1016/S0140-6736(17)30565-2. View

Marino-Enriquez A, Wang W, Roy A, Lopez-Terrada D, Lazar A, Fletcher C . Epithelioid inflammatory myofibroblastic sarcoma: An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK. Am J Surg Pathol. 2010; 35(1):135-44. DOI: 10.1097/PAS.0b013e318200cfd5. View

Cohen J, Yeh I, Jordan R, Wolsky R, Horvai A, McCalmont T . Cutaneous Non-Neural Granular Cell Tumors Harbor Recurrent ALK Gene Fusions. Am J Surg Pathol. 2018; 42(9):1133-1142. DOI: 10.1097/PAS.0000000000001122. View

10.

Granato M, Gilardini Montani M, Zompetta C, Santarelli R, Gonnella R, Romeo M . Quercetin Interrupts the Positive Feedback Loop Between STAT3 and IL-6, Promotes Autophagy, and Reduces ROS, Preventing EBV-Driven B Cell Immortalization. Biomolecules. 2019; 9(9). PMC: 6769872. DOI: 10.3390/biom9090482. View

11.

Iyevleva A, Raskin G, Tiurin V, Sokolenko A, Mitiushkina N, Aleksakhina S . Novel ALK fusion partners in lung cancer. Cancer Lett. 2015; 362(1):116-21. DOI: 10.1016/j.canlet.2015.03.028. View

12.

Griffin C, Hawkins A, Dvorak C, Henkle C, Ellingham T, Perlman E . Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res. 1999; 59(12):2776-80. View

13.

Lee J, Li C, Huang H, Zhu M, Marino-Enriquez A, Lee C . ALK oncoproteins in atypical inflammatory myofibroblastic tumours: novel RRBP1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma. J Pathol. 2016; 241(3):316-323. PMC: 5337428. DOI: 10.1002/path.4836. View

14.

Poh C, Priddy R, Dahlman D . Intramandibular inflammatory myofibroblastic tumor--a true neoplasm or reactive lesion?. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005; 100(4):460-6. DOI: 10.1016/j.tripleo.2004.07.005. View

15.

Lee C, Schoffski P, Modave E, van Wezel T, Boeckx B, Sufliarsky J . Comprehensive Molecular Analysis of Inflammatory Myofibroblastic Tumors Reveals Diverse Genomic Landscape and Potential Predictive Markers for Response to Crizotinib. Clin Cancer Res. 2021; 27(24):6737-6748. DOI: 10.1158/1078-0432.CCR-21-1165. View

16.

Taniguchi K, Konishi H, Yoshinaga A, Tsugane M, Takahashi H, Nishisaka F . Efficacy of combination treatment using YHO-1701, an orally active STAT3 inhibitor, with molecular-targeted agents on cancer cell lines. Sci Rep. 2021; 11(1):6685. PMC: 7988006. DOI: 10.1038/s41598-021-86021-8. View

17.

DAmore E, Visco C, Menin A, Famengo B, Bonvini P, Lazzari E . STAT3 pathway is activated in ALK-positive large B-cell lymphoma carrying SQSTM1-ALK rearrangement and provides a possible therapeutic target. Am J Surg Pathol. 2013; 37(5):780-6. DOI: 10.1097/PAS.0b013e318287791f. View

18.

Siemion K, Reszec-Gielazyn J, Kisluk J, Roszkowiak L, Zak J, Korzynska A . What do we know about inflammatory myofibroblastic tumors? - A systematic review. Adv Med Sci. 2022; 67(1):129-138. DOI: 10.1016/j.advms.2022.02.002. View

19.

Casanova M, Brennan B, Alaggio R, Kelsey A, Orbach D, van Noesel M . Inflammatory myofibroblastic tumor: The experience of the European pediatric Soft Tissue Sarcoma Study Group (EpSSG). Eur J Cancer. 2020; 127:123-129. DOI: 10.1016/j.ejca.2019.12.021. View

20.

von Mehren M, Kane J, Agulnik M, Bui M, Carr-Ascher J, Choy E . Soft Tissue Sarcoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022; 20(7):815-833. PMC: 10186762. DOI: 10.6004/jnccn.2022.0035. View